Microbial Therapeutics in Neurocognitive and Psychiatric Disorders

被引:16
作者
Alagiakrishnan, Kannayiram [1 ]
Halverson, Tyler [2 ]
机构
[1] Univ Alberta, Dept Med, Div Geriatr Med, Clin Sci Bldg,11350-83 Ave, Edmonton, AB T6G 2P4, Canada
[2] Univ Alberta, Dept Med, Div Psychiat, Edmonton, AB, Canada
来源
JOURNAL OF CLINICAL MEDICINE RESEARCH-CANADA | 2021年 / 13卷 / 09期
关键词
Gut biotics; Probiotics; Prebiotics; Synbiotics; Parapro-biotics proteobiotics; Postbiotics; Life style factors; Psychiatric dis-eases; Neurocognitive disorders;
D O I
10.14740/jocmr4575
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Microbial therapeutics, which include gut biotics and fecal transplantation, are interventions designed to improve the gut microbiome. Gut biotics can be considered as the administration of direct microbial populations. The delivery of this can be done through live microbial flora, certain food like fiber, microbial products (metabolites and elements) obtained through the fermentation of food products, or as genetically engineered substances, that may have therapeutic benefit on different health disorders. Dietary intervention and pharmacological supplements with gut biotics aim at correcting disruption of the gut microbiota by repopulating with beneficial microorganism leading to decrease in gut permeability, inflammation, and alteration in metabolic activities, through a variety of mechanisms of action. Our understanding of the pharmacokinetics of microbial therapeutics has improved with in vitro models, sampling techniques in the gut, and tools for the reliable identification of gut biotics. Evidence from human studies points out that prebiotics, probiotics and synbiotics have the potential for treating and preventing mental health disorders, whereas with paraprobiotics, proteobiotics and postbiotics, the research is limited at this point. Some animal studies point out that gut biotics can be used with conventional treatments for a synergistic effect on mental health disorders. If future research shows that there is a possibility of synergistic effect of psychotropic medications with gut biotics, then a gut biotic or nutritional prescription can be given along with psychotropics. Even though the overall safety of gut biotics seems to be good, caution is needed to watch for any known and unknown side effects as well as the need for risk benefit analysis with certain vulnerable populations. Future research is needed before wide spread use of natural and genetically engineered gut biotics. Regulatory framework for gut biotics needs to be optimized. Holistic understanding of gut dysbiosis, along with life style factors, by health care providers is necessary for the better management of these conditions. In conclusion, microbial therapeutics are a new psychotherapeutic approach which offer some hope in certain conditions like dementia and depression. Future of microbial therapeutics will be driven by welldone randomized controlled trials and longitudinal research, as well as by replication studies in human subjects.
引用
收藏
页码:439 / 459
页数:21
相关论文
共 73 条
[1]   Gut-brain actions underlying comorbid anxiety and depression associated with inflammatory bowel disease [J].
Abautret-Daly, Aine ;
Dempsey, Elaine ;
Parra-Blanco, Adolfo ;
Medina, Carlos ;
Harkin, Andrew .
ACTA NEUROPSYCHIATRICA, 2018, 30 (05) :275-296
[2]   LRRK2 kinase in Parkinson's disease [J].
Alessi, Dario R. ;
Sammler, Esther .
SCIENCE, 2018, 360 (6384) :36-37
[3]   Human gut microbiota: the links with dementia development [J].
Alkasir, Rashad ;
Li, Jing ;
Li, Xudong ;
Jin, Miao ;
Zhu, Baoli .
PROTEIN & CELL, 2017, 8 (02) :90-102
[4]   Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities [J].
Ananthakrishnan, Ashwin N. ;
Donaldson, Tamara ;
Lasch, Karen ;
Yajnik, Vijay .
INFLAMMATORY BOWEL DISEASES, 2017, 23 (06) :882-893
[5]   Systematic Review and Meta-analysis: Phenotype and Clinical Outcomes of Older-onset Inflammatory Bowel Disease [J].
Ananthakrishnan, Ashwin N. ;
Shi, Hai Yun ;
Tang, Whitney ;
Law, Cindy C. Y. ;
Sung, Joseph J. Y. ;
Chan, Francis K. L. ;
Ng, Siew C. .
JOURNAL OF CROHNS & COLITIS, 2016, 10 (10) :1224-1236
[6]   Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease [J].
Bernstein, Charles N. ;
Hitchon, Carol A. ;
Walld, Randy ;
Bolton, James M. ;
Sareen, Jitender ;
Walker, John R. ;
Graff, Lesley A. ;
Patten, Scott B. ;
Singer, Alexander ;
Lix, Lisa M. ;
El-Gabalawy, Renee ;
Katz, Alan ;
Fisk, John D. ;
Marrie, Ruth Ann .
INFLAMMATORY BOWEL DISEASES, 2019, 25 (02) :360-368
[7]   Inflammatory Bowel Diseases and Parkinson's Disease [J].
Brudek, Tomasz .
JOURNAL OF PARKINSONS DISEASE, 2019, 9 :S331-S344
[8]   Neuroinflammation in Alzheimer's disease: Current evidence and future directions [J].
Calsolaro, Valeria ;
Edison, Paul .
ALZHEIMERS & DEMENTIA, 2016, 12 (06) :719-732
[9]   Inflammatory bowel disease and risk of Parkinson's disease in Medicare beneficiaries [J].
Camacho-Soto, Alejandra ;
Gross, Anat ;
Nielsen, Susan Searles ;
Dey, Neelendu ;
Racette, Brad A. .
PARKINSONISM & RELATED DISORDERS, 2018, 50 :23-28
[10]   Gastrointestinal Problems in Children with Autism, Developmental Delays or Typical Development [J].
Chaidez, Virginia ;
Hansen, Robin L. ;
Hertz-Picciotto, Irva .
JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 2014, 44 (05) :1117-1127